Top Analyst Reports for T-Mobile, AstraZeneca & Comcast

Tuesday, July 8, 2025

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), AstraZeneca PLC (AZN) and Comcast Corp. (CMCSA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> Pre-Markets Mixed at Start of Prime Day, Awaiting Trade Deals

Today's Featured Research Reports

T-Mobile’s shares have outperformed the Zacks Wireless National industry over the past year (+34.5% vs. +30.7%). The company is benefiting from industry-leading postpaid customer growth with a record-low churn rate. Its acquisition strategy has significantly strengthened its position in the wireless industry over the past few years. 

TMUS’ 2.5 GHz 5G spectrum delivers superfast speeds and extensive coverage with signals that go through walls and trees. This boosts its competitive edge against companies that provide 5G networks controlled by the mmWave spectrum. 

However, owing to the stock’s premium valuation, we believe investors should remain cautious as macroeconomic factors, market saturation, or economic downturns can significantly impact overvalued stocks like TMUS. Fierce competition is straining profitability. To lure customers from competitors, T-Mobile has launched several low-priced service plans for consumers. This has put pressure on profits.

(You can read the full research report on T-Mobile here >>>)

Shares of AstraZeneca have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+7.7% vs. -2%). The company’s key drugs like Lynparza, Tagrisso, Imfinzi and Fasenra should keep driving revenues. Its pipeline is strong, with pivotal late- and mid-stage pipeline data readouts lined up. 

AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline. AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. 

However, potentially lower sales of Lynparza and Farxiga in China, the impact of Part D redesign on U.S. oncology sales and slowing sales of rare disease drugs are expected to hurt the top line in 2025. Estimates have declined slightly ahead of the Q2 earnings release. The company has a mixed record of earnings surprises in recent quarters.

(You can read the full research report on AstraZeneca here >>>)

Comcast’s shares have underperformed the Zacks Cable Television industry over the year-to-date period (-3.1% vs. +4.2%). The company has been persistently suffering from video-subscriber attrition due to cord-cutting. Broadband prospects are suffering from increased competition from fixed wireless and fiber businesses. 

Theme Parks revenues declined due to lower revenues at domestic theme parks, driven by lower guest attendance, including the impact of the Hollywood wildfires. A leveraged balance sheet is a major concern for Comcast. 

Nevertheless, steady growth in Content & Experiences revenues driven by steady performances by Studios and Media segments is positive. Its streaming service, Peacock, has been a key catalyst in driving broadband sales. Decreasing programming & production costs bode well for CMCSA's profitability. Strong free cash flow generation ability is noteworthy. 

(You can read the full research report on Comcast here >>>)

Other noteworthy reports we are featuring today include Entergy Corp. (ETR), Align Technology, Inc. (ALGN) and Universal Health Services, Inc. (UHS).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

T-Mobile (TMUS) Rides on Solid 5G Expansion, Strong Cash Flow

Key Drugs Aid AstraZeneca (AZN) Sales, Pipeline Strong

Domestic Wireless Subscriber Gain Benefits Comcast (CMCSA)

Featured Reports

Investments Aid ETR Corporation (ETR) Amid Poor Solvency
Per the Zacks analyst, ETR Corp. makes disciplined investment to maintain and upgrade the reliability of its electric utility systems. Yet its poor financial ratios indicate weak solvency position.

Align (ALGN) Rides on Growing Invisalign Volume, Innovation
The Zacks analyst is optimistic about Align's strong market rollout of several Invisalign products globally. The company's focused efforts to expand portfolio aids growth.

Rising Admissions Aid Universal Health (UHS), High Costs Ail
Per the Zacks analyst, Universal Health's continued growth in admissions at its acute care facilities will boost its top line. However, escalating expenses remain a concern for the company.

Strong SMB clientele Aids BILL Holdings' (BILL) Prospects
Per the Zacks analyst, BILL is benefiting from an expanding small and medium business (SMB) clientele, as well as a diversified business model.

Expanding Customer Base & Smart Investment Aid ONE Gas (OGS)
Per the Zacks analyst, ONE Gas is set to benefit from capital expenditure plan and extension of services to new areas. Steady demand from residential customers boosts its performance.

Business Growth Plans Aid Boise Cascade (BCC), Macro Risks Ail
Per the Zacks analyst, Boise Cascade is gaining from accretive business growth strategies, while ensuring shareholder value. However, housing market softness and macro risks hurt prospects.

Sarepta (SRPT) Growth Outlook Dimmed by Elevidys Concerns
Though Sarepta's pipeline of LGMD therapies holds potential, the Zacks analyst is concerned with two Elevidys-linked deaths and their impact on topline growth.

New Upgrades

Loan Growth & Strong Liquidity Supports SouthState (SSB)
Per the Zacks analyst, SouthState's expanding loan balance and solid non-interest income will aid top-line growth. Its strong liquidity position enables sustainable capital distributions.

SkyWest (SKYW) Benefits From Improving Air-Travel Demand
The Zacks Analyst is impressed with the fact that increased air-travel demand is helping SkyWest carry more passengers and witness more revenues.

TreeHouse Foods (THS) Drives Growth with Supply Chain Wins
Per the Zacks analyst, TreeHouse Foods accelerates margin expansion with supply chain efficiencies, streamlined operations, and a focused portfolio in high-growth private label categories.

New Downgrades

Expected Decline in Sales & High Capex to Ail Magna (MGA)
Per the Zacks analyst, Magna's 2025 revenues are expected to decline due to lower light vehicle production in North America. High capex requirement is likely to strain near-term cash flows.

Trucking Costs & Oil Price Swings to Ail Vista Energy (VIST)
Per the Zacks analyst, Vista Energy's heavy reliance on trucking for transporting production and its exposure to volatile international oil prices are expected to weigh on its profitability.

Weak Digital Sales Hurts Bath & Body Works' (BBWI) Growth
Per the Zacks analyst, despite favorable foot traffic, BBWI's digital softness in first quarter suggests cracks in its e-commerce strategy that could weigh on future performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research